Moreover, analyses of TCGA tumour data demonstrated that GSK3α and GSK3β mRNA levels are specifically increased in BRCA1/2-mutated breast tumours (Supplementary Fig. 3b), suggesting GSK3 as a potential clinical target for tumours lacking BRCA function. This evidence concerns the gene GSK3A and neoplasm.